Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.
Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.
These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.
Tango Therapeutics received a Schedule 13G/A amendment from The Vanguard Group reporting 0 shares of Common Stock, representing 0% of the class. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538; as a result, The Vanguard Group no longer reports beneficial ownership of those securities. The amendment is signed by Ashley Grim on March 27, 2026.
TNGX reports a proposed sale of 93,000 shares of Common Stock related to the exercise of stock options on 03/25/2026 for cash. The filing also lists prior Rule 10b5-1 sales by Adam Crystal, including 20,251, 54,345, and 18,452 shares on 03/05/2026, 02/25/2026, and 02/03/2026, respectively.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an open-market sale of 20,251 shares of common stock at $15.00 per share. After this transaction, she directly owned 112,622 shares of Tango Therapeutics common stock.
The sale was executed on March 5, 2026 and is described as an open-market or private transaction. According to a footnote, these trades were carried out under a pre-established Rule 10b5-1 trading plan adopted on October 27, 2025, which automates transactions under preset instructions.
Adam Crystal submitted a Form 144 reporting proposed dispositions of Common stock tied to option exercises and restricted stock units, and disclosing recent 10b5-1 sales. The filing lists an exercise of stock options for 15,000 shares on 03/05/2026 (cash), and restricted stock units totaling 5,251 with an award date of 02/03/2025.
The filing also reports completed 10b5-1 sales by Adam Crystal: 54,345 shares sold on 02/25/2026 for $694,208.46, and 18,452 shares sold on 02/03/2026 for $226,300.30.
Tango Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided pipeline and corporate updates. Cash, cash equivalents and marketable securities totaled $343.1 million as of December 31, 2025, which the company expects will fund operations into 2028.
Collaboration revenue was $62.4 million for 2025, up from $30.0 million in 2024, mainly reflecting recognition of remaining Gilead deferred revenue. Research and development expenses declined to $132.2 million from $143.9 million, while net loss narrowed to $101.6 million, or $0.87 per share, from $130.3 million, or $1.19 per share. The company highlighted progress for lead PRMT5 inhibitor vopimetostat, plans for a pivotal 2L pancreatic cancer study in 2026, new combination collaborations, and leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics, Inc. files its 2025 annual report outlining an advanced pipeline of precision oncology programs built around synthetic lethality and biomarker-driven patient selection.
The company highlights vopimetostat (TNG462), a PRMT5 inhibitor for MTAP‑deleted cancers, with Phase 1/2 monotherapy data showing a 27% objective response rate and 6.4‑month median progression‑free survival across 94 evaluable patients, including 7.2‑month median progression‑free survival and 25% response rate in second‑line MTAP‑deleted pancreatic cancer. A histology‑selective cohort reported a 49% response rate and 9.1‑month median progression‑free survival. Combination trials with RAS(ON) inhibitors daraxonrasib and zoldonrasib are under way, along with a new collaboration with Erasca’s pan‑RAS agent ERAS‑0015.
TNG456, a brain‑penetrant PRMT5 inhibitor, is in a Phase 1/2 trial for MTAP‑deleted solid tumors with a focus on glioblastoma, supported by pharmacokinetics suggesting adequate central nervous system exposure; earlier candidate TNG908 was discontinued after subtherapeutic brain exposure. TNG961, an HBS1L degrader for FOCAD‑deleted/MTAP‑deleted tumors, remains in IND‑enabling development. CoREST inhibitor TNG260, combined with pembrolizumab, delivered a 29‑week median progression‑free survival in a five‑patient subgroup of checkpoint‑inhibitor‑resistant STK11‑mutant/KRAS wild‑type non‑small cell lung cancer, more than double the ~10‑week standard of care, and is continuing in that genetically defined cohort.
Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.
Adam Crystal filed a Form 144 reporting sales of company common stock. The filing lists 54,345 Restricted Stock Units identified for sale and reports 18,452 shares sold on 02/03/2026 for $226,300.30.
The filing names Morgan Stanley Smith Barney LLC as the broker and shows transaction and security details tied to restricted stock units dated 02/05/2024.